PolyPeptide Group AG (LON:0AAJ)
London · Delayed Price · Currency is GBP · Price in CHF | Market Cap | 796.20M |
| Revenue (ttm) | 316.17M |
| Net Income (ttm) | -29.76M |
| Shares Out | n/a |
| EPS (ttm) | -0.89 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 16,557 |
| Average Volume | 13,608 |
| Open | 25.45 |
| Previous Close | 25.60 |
| Day's Range | 25.08 - 25.75 |
| 52-Week Range | 13.82 - 30.25 |
| Beta | 1.12 |
| RSI | 52.54 |
| Earnings Date | Mar 12, 2026 |
About PolyPeptide Group AG
PolyPeptide Group AG operates as a contract development and manufacturing company in Europe, the United States, and India. It develops and manufactures synthetic peptides and oligonucleotides used as active pharmaceutical ingredients or intermediates in therapeutic products for pharmaceutical and biotech companies. The company offers portfolio of drug therapies for metabolic diseases, including the GLP-1. It also provides generic peptides and peptides used in cosmetics, animal health, and medical devices. PolyPeptide Group AG was founded in 195... [Read more]
Financial Performance
In 2024, PolyPeptide Group AG's revenue was 336.79 million, an increase of 5.13% compared to the previous year's 320.37 million. Losses were -19.56 million, -61.97% less than in 2023.
Financial numbers in EUR Financial StatementsNews
Lupin subsidiary forms long-term strategic alliance with PolyPeptide Group to strengthen global peptide supply chain
Lupin Manufacturing Solutions (LMS), a subsidiary of pharma giant Lupin Limited, has entered into a long-term strategic alliance with PolyPeptide...